Ac2-26 TFA

Cat. No.:	HY-P1098A
Molecular Formula:	$C_{143}H_{211}F_3N_{32}O_{46}S$
Molecular Weight:	3203.45
Sequence:	Ac-Ala-Met-Val-Ser-Glu-Phe-Leu-Lys-Gln-Ala-Trp-Phe-Ile-Glu-Asn-Glu-Glu-Gln-Glu-Tyr-Val-Gln-Thr-Val-Lys Ac-AMVSEFLKQAWFIENEEQEYVQTVK (TFA salt)
Sequence Shortening:	Ac-AMVSEFLKQAWFIENEEQEYVQTVK
Target:	NF-κB
Pathway:	NF-κB
Storage:	Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

SOLVENT & SOLUBILITY

In Vitro	H_2O : 0.11 mg/mL (0.03 mM; ultrasonic and adjust pH to 13 with NaOH) DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble)
In Vivo	1. Add each solvent one by one: PBS Solubility: 1 mg/mL (0.31 mM); Clear solution; Need ultrasonic and adjust pH to 9 with NaOH

BIOLOGICAL ACTIVITY

Description	Ac2-26 TFA, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury. Ac2-26 also decreases AnxA1 protein expression, inhibits the activation of NF-κB and MAPK pathways in the injured lung tissue[1].

CUSTOMER VALIDATION

- Cancer Cell. 2023 May 8;41(5):903-918.e8.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Liao WI, et al. Ac2-26, an Annexin A1 Peptide, Attenuates Ischemia-Reperfusion-Induced Acute Lung Injury. Int J Mol Sci. 2017 Aug 15;18(8). pii: E1771.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA